KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Assets Average: 2021-2025

Historic Assets Average for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $1.4 billion.

  • AbCellera Biologics' Assets Average fell 1.68% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1.68%. This contributed to the annual value of $1.4 billion for FY2024, which is 5.95% down from last year.
  • Per AbCellera Biologics' latest filing, its Assets Average stood at $1.4 billion for Q3 2025, which was up 0.43% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Assets Average ranged from a high of $1.6 billion in Q2 2022 and a low of $1.1 billion during Q1 2021.
  • Its 3-year average for Assets Average is $1.4 billion, with a median of $1.4 billion in 2024.
  • In the last 5 years, AbCellera Biologics' Assets Average soared by 39.72% in 2022 and then fell by 8.35% in 2025.
  • Over the past 5 years, AbCellera Biologics' Assets Average (Quarterly) stood at $1.2 billion in 2021, then grew by 24.16% to $1.5 billion in 2022, then declined by 3.01% to $1.5 billion in 2023, then decreased by 8.23% to $1.4 billion in 2024, then dropped by 1.68% to $1.4 billion in 2025.
  • Its Assets Average stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.4 billion for Q1 2025.